检索历史 清除

随着近视眼在我国发病率逐年增高及各种治疗技术不断进步，激光角膜屈光手术成为矫正屈光不正的重要方式之一，围手术期的合理用药是保证手术成功、降低并发症的重要环节。2019年基于我国激光角膜屈光手术的发展状况，中国微循环委员会眼微循环屈光专业委员会与中华医学会眼科学分会相关专业学组的专家经过讨论，发布《中国激光角膜屈光手术围手术期用药专家共识（2019年）》。为了进一步推动临床新的技术和手术方法不断拓展，满足其推广需求，提高手术疗效，中国微循环委员会眼微循环屈光专业委员会基于最新国内外研究结果，针对激光角膜屈光手术的围手术期用药再次进行集体讨论，达成进一步共识性意见。

With the increasing incidence of myopia year by year and the continuous progress of various treatment techniques, laser corneal refractive surgery has become one of the important ways to correct refractive errors. The rational drug use in the perioperative period is important for the success of surgery and reduction of complications. In 2019, based on the development of laser corneal refractive surgery in China, experts from the Refractive Surgery Experts Group of Ocular Microcirculation Branch of Chinese Society of Microcirculation and the Ophthalmology Branch in the Chinese Medical Association formed the "Chinese Expert Consensus on the Perioperative Medication in Laser Corneal Refractive Surgery (2019)". To further promote the expansion of new clinical technologies and surgical methods, and to improve surgical efficacy, the Refractive Surgery Experts Group of Ocular Microcirculation Branch of Chinese Society of Microcirculation, according to the latest domestic and foreign research results, has recently updated the consensus after a collective discussion.